Oncology Sponsored Global oncology innovation from Hengrui Pharma Hengrui Pharma's strategic ambition in oncology has focused on translating scientific innovation into meaningful treatment options for patients.
Oncology What will ASCO 2026 reveal about oncology innovation’s new g... The next leaders in oncology will be the ones built to adapt in real time.
R&D The devil’s in the details: Navigating complexity & nuance i... Clinical trial expansion comes with complexity and increased risk, as each country has distinct regulatory requirements and contractual expectations.
Market Access Sustaining the mature product portfolio through strategic ou... Globalisation and the growth of emerging markets has created new opportunities to expand the reach for the mature portfolio.
Oncology The importance of globalisation for patient access At ESMO 2025 in Berlin, pharmaphorum spoke with Jo Feng, president of Hengrui Pharma.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.